Advertisement
UK markets closed
  • FTSE 100

    7,820.36
    -145.17 (-1.82%)
     
  • FTSE 250

    19,344.54
    -354.35 (-1.80%)
     
  • AIM

    738.28
    -12.00 (-1.60%)
     
  • GBP/EUR

    1.1696
    -0.0014 (-0.12%)
     
  • GBP/USD

    1.2431
    -0.0016 (-0.13%)
     
  • Bitcoin GBP

    49,750.36
    -2,331.47 (-4.48%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,061.53
    -0.29 (-0.01%)
     
  • DOW

    37,897.99
    +162.88 (+0.43%)
     
  • CRUDE OIL

    85.48
    +0.07 (+0.08%)
     
  • GOLD FUTURES

    2,404.30
    +21.30 (+0.89%)
     
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     
  • DAX

    17,766.23
    -260.35 (-1.44%)
     
  • CAC 40

    7,932.61
    -112.50 (-1.40%)
     

The Zacks Analyst Blog Highlights: Johnson & Johnson, Morgan Stanley, Sinopec, American Electric Power and Kinder Morgan

For Immediate Release

Chicago, IL – February 26, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson JNJ, Morgan Stanley MS, Sinopec SNP, American Electric Power AEP and Kinder Morgan KMI.

Here are highlights from Tuesday’s Analyst Blog:

Top Research Reports for Johnson & Johnson, Morgan Stanley and Sinopec

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Morgan Stanley and Sinopec. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

ADVERTISEMENT

You can see all of today’s research reports here >>>

Johnson & Johnson’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+7.2% vs. +5.3%). The Zacks analyst believes that J&J is witnessing significant generic/biosimilar headwinds in the Pharma unit.

However, the unit is performing above-market levels, supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara. J&J is also making rapid progress with its pipeline and line extensions.

It gained FDA approval for two new drugs in 2019, Balversa and Spravato. Several pivotal data readouts and regulatory milestones are expected in 2020. Headwinds like biosimilar/generic competition and pricing pressure remain. J&J faces numerous lawsuits, which allege personal injuries to patients caused by the use of its products. These lawsuits have resulted in uncertainty.

Shares of Morgan Stanley have gained +23.7% in the past six months against the Zacks Investment Banking industry’s rise of +16.8%. The Zacks analyst believes that the company’s planned acquisition of E*Trade Financial for $13 billion will further support Wealth Management business.

Improving economy and focus on corporate lending operation are expected to continue supporting profitability. The company has an impressive earnings surprise history, having outpaced the Zacks Consensus Estimate in each of the trailing four quarters.

Although dependence on capital markets to generate trading and investment banking revenues, lower rates and continuously rising operating expenses are major near-term concerns, initiatives to further strengthen investment management operation are likely to support top-line growth. Also, enhanced capital deployment activities reflect a strong balance sheet position and will enhance shareholder value.

Sinopec’s shares have lost 9.2% over the past three months against the Zacks Integrated Oil industry’s fall of 7.3%. The Zacks analyst believes that Sinopec’s natural gas business has immense potential for growth over the coming years as China intends to move from coal to natural gas.

Sinopec is among the largest integrated energy players in China, with significant presence in upstream and downstream businesses. Further, the company has made major progress in identifying economically-viable oil & gas reserves. A huge scale of prospective new reserves was discovered in a number of prolific oil & gas resources like Sichuan Basin & Jiyang Depression.

However, the disruption in China’s economy owing to the outbreak of coronavirus will continue to hurt the firm’s refining business. With declining demand for chemical products, the firm’s chemicals operations are expected to take a hit.

Other noteworthy reports we are featuring today include American Electric Power and Kinder Morgan.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report American Electric Power Company, Inc. (AEP) : Free Stock Analysis Report Morgan Stanley (MS) : Free Stock Analysis Report China Petroleum & Chemical Corporation (SNP) : Free Stock Analysis Report Kinder Morgan, Inc. (KMI) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research